Retatrutide (GLP-3 | GIP | Glucagon)

Name: Retatrutide (GLP-3 | GIP | Glucagon)
Availability: InStock

$90.00

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly. It is a first-in-class triple hormone receptor agonist that simultaneously activates three metabolic pathways: GLP-1, GIP, and Glucagon receptors.

Category: Buy PEPTIDES

Description
Reviews (0)

Buy Retatrutide (GLP-3 | GIP | Glucagon)

In 2026, Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly. It is a first-in-class triple hormone receptor agonist that simultaneously activates three metabolic pathways: GLP-1, GIP, and Glucagon receptors.

Mechanism of Action (“Triple G”)

Retatrutide is often called the “triple G” drug because it targets three key hunger-regulating hormone receptors:

GLP-1 (Glucagon-like peptide-1): Reduces appetite, slows digestion, and helps regulate blood sugar.
GIP (Glucose-dependent insulinotropic polypeptide): Supports insulin response and fat metabolism while limiting food cravings.
Glucagon (GCG): Increases energy expenditure and promotes the body’s ability to burn stored fat.

Topline Clinical Results (2026 Update)

Recent results from Phase 3 trials have set new standards for non-surgical weight loss:

- - Weight Reduction: In the TRIUMPH-4 trial released in late 2025, participants on the highest dose (12mg) lost an average of 28.7% (nearly 71 lbs) of their body weight over 68 week
  - Disease Complications: The drug showed a 75.8% reduction in knee pain for participants with obesity and knee osteoarthritis Retatrutide (GLP-3 | GIP | Glucagon).
  - Metabolic Markers: It has demonstrated significant reductions in liver fat (up to 82%), blood pressure, and non-HDL cholesterol.

Side Effects and Safety

Consistent with other incretin-based therapies, side effects are primarily gastrointestinal, including nausea, diarrhea, constipation, and vomiting. A new safety signal, dysesthesia (abnormal sense of touch), was reported in up to 20.9% of participants on high doses in recent trials.

Approval Status and Availability

- FDA Status: As of January 2026, Retatrutide is not FDA-approved.
- Projected Timeline: With seven Phase 3 readouts expected throughout 2026, experts anticipate potential FDA approval as early as late 2026 or 2027.Access: It is currently only available legally through participation in registered clinical trials. Any online versions marketed for sale in 2026 are unapproved and potentially unsafe
- the uses for Retatrutide, Oxytocin, NAD+, and Glutathione span from advanced metabolic correction to cellular longevity and emotional wellness.
  
  1. Retatrutide (Metabolic & Weight Management)
  
  As a “triple agonist” (GLP-1/GIP/Glucagon), Retatrutide is used in clinical research for the most aggressive forms of metabolic treatment:
  - Massive Weight Loss: Used to achieve body weight reductions of 25% to 29%, often used as an alternative for patients who did not reach their goals on Semaglutide or Tirzepatide.
  - MASH (Fatty Liver) Resolution: Because of the glucagon component, it is used to specifically target and “burn” fat stored in the liver.
  - Energy Expenditure: Unlike other GLP-1s that only suppress appetite, Retatrutide is used to increase the body’s resting metabolic rate.